Histone deacetylase inhibitors in cancer therapy
- 26 April 2007
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 16 (5) , 659-678
- https://doi.org/10.1517/13543784.16.5.659
Abstract
(2007). Histone deacetylase inhibitors in cancer therapy. Expert Opinion on Investigational Drugs: Vol. 16, No. 5, pp. 659-678. doi: 10.1517/13543784.16.5.659Keywords
This publication has 135 references indexed in Scilit:
- Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cellsBlood, 2006
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitorBlood, 2006
- Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell LymphomaClinical Cancer Research, 2006
- Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerNature Genetics, 2005
- Anti‐tumor mechanisms of valproate: A novel role for an old drugMedicinal Research Reviews, 2002
- Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cellsZeitschrift für Krebsforschung und Klinische Onkologie, 1997
- Derivatives of butyric acid as potential anti‐neoplastic agentsInternational Journal of Cancer, 1991